Companies: Epigenomics

The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.

The German molecular diagnostics firm recently completed a capital increase with subscription rights for existing shareholders, grossing €22.3 million.

The revenue growth was driven by strong sales of products including the company's Epi proColon blood-based colorectal cancer screening test.

The higher revenues were driven by a 38 percent increase in product sales, which include the company's Epi proColon blood-based colorectal cancer screening test.

The company attributed the decline in part to fewer orders for its Epi proColon colorectal cancer test.

The firm's blood-based Epi proLung lung cancer test looks for a combination of DNA methylation biomarkers.

The company will use the net proceeds to finance its current operations and expand its US commercialization capacities for its lead product, Epi proColon.

The drop off was attributed to unusually high revenues in Q2 2016 after a commercialization partner stocked up on Epigenomics' colon cancer test.

The change comes amid lower than expected revenues for the first half of this year, as well as an anticipated continued lack of reimbursement coverage in the US. 

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

In Science this week: reduction in bee phylogenetic diversity, and more.